




Parkinson's Disease

Parkinson's disease is a progressive CNS inflammatory disorder that affects movement. Parkinson's disease is caused by a loss of nerve cells in the part of the brain called the substantia nigra. The **MAP** Biomarker has the potential to lead to an earlier more accurate diagnosis and monitoring of **PD** leading to earlier treatment and potentially better outcomes.



MYND ANTICIPATES UTILIZING THE MAP BIOMARKER TO EFFECTIVELY DIAGNOSE AND MONITOR PD FROM AN OBJECTIVE AND TIMELY MOLECULAR APPROACH.

Today, there is **no single diagnostic test** that can determine if a person has Parkinson's Disease

- Early diagnosis of Parkinson's Disease is extremely difficult. Patients must display several symptoms over an extended period of time. This essentially allows the disease to progress prior to treatment responses in order to objectively make a diagnosis
- The **MAP** Biomarker has the potential to allow researchers the ability to objectively measure the progression of PD. **mynd** will have the ability to commercialize **MAP** and make it available to the general public through healthcare practitioners once the evidence has been gathered to make a submission to the FDA, potentially in the second half of 2022.